MOTS-c
Reviews describe MOTS-c as a peptide encoded in mitochondrial DNA rather than the cell nucleus, and report activation of the energy-sensing enzyme AMPK and regulation of the folate–methionine cycle in laboratory models.
Full reference page →
Research area
Mitochondrial & Cellular Energy
Research into cellular energy pathways, mitochondrial function, stress adaptation, and metabolic signalling — the layer beneath whole-body metabolism, where the cell decides what to do with the energy it has.
- Compound classes
- 3Compound classes
- Randomised human trials
- 41Randomised human trials
- Field references
- 12Field references
- Last retrieved
- 2026-08-03Last retrieved
Read at your level
The standard reading.
Most metabolic and longevity work describes signals travelling between organs. Cellular energy sits a level down, inside the cell, where the mitochondrion turns fuel into usable energy and reports back on how that conversion is going. The field is interesting to peptide science for a specific reason: mitochondria carry their own small genome, and some of the short gene-like stretches (open reading frames) in it appear to encode peptides.
MOTS-c is the most studied of these. It is encoded in mitochondrial DNA rather than the DNA in the cell nucleus, which makes it a genuinely unusual object — a signalling molecule that comes from the mitochondrion itself. Reviews describe it in relation to AMPK, the enzyme that reads the balance of AMP to ATP — the cell’s low- and high-energy markers — and switches metabolism between building up and breaking down.
Alongside that sits the NAD+ literature. NAD+ is a helper molecule (a coenzyme) required for the energy-releasing reactions of metabolism, and it is also used up as a substrate by sirtuins and PARPs, so how much is available connects the cell’s energy status to enzymes that regulate a great deal else. It carries the largest human trial count in this field by a wide margin.
Significance
Why this area is studied
Cellular energy is where a lot of otherwise unrelated biology converges — metabolism, stress response, and ageing research all end up describing the same enzymes. That convergence is what makes the area worth understanding, and also what makes it easy to overread: a pathway that touches many processes invites the assumption that changing it improves all of them, which the evidence here does not support.
Mechanism
The science, in plain terms
Energy sensing by AMPK
AMPK reads the balance of AMP to ATP and acts as a switch between building molecules up (anabolic) and breaking them down (catabolic). It is the cell-level counterpart to the hormonal signals described in metabolic research, and it is the mechanism most frequently invoked in the literature on mitochondrial-derived peptides.
Peptides encoded in mitochondrial DNA
Mitochondria keep a small circular genome, and short gene-like stretches (open reading frames) within it have been reported to encode peptides that act outside the mitochondrion. Reviews treat this as a mechanism still being characterised rather than an established signalling axis.
NAD+ as substrate, not just cofactor
Beyond its role in energy-releasing reactions, NAD+ is consumed by sirtuins and PARPs, which means enzyme activity in those families is limited by how much is available. That consuming relationship is why the supply of NAD+ building blocks (precursors) is studied at all.
Practice
How the research is conducted
The study designs that generate evidence in this area. Each carries its own interpretive limits — which is why the evidence hierarchy is worth reading alongside them.
- 01
Respirometry and oxygen-consumption assays measuring mitochondrial function in isolated cells
- 02
Rodent models of metabolic and exercise stress, examining adaptation rather than performance
- 03
Measurement of tissue NAD+ and its precursors before and after supplementation in controlled human studies
- 04
Cell-based tests of AMPK’s activation state (its phosphorylation) as a readout of energy-sensing activity
Open questions
What researchers are still testing
These are questions under investigation, not expected outcomes. Listing them is a description of where the field’s attention currently sits — not a suggestion that any of them will resolve favourably.
- 01
Whether a peptide encoded in the mitochondria, when supplied from outside the cell, reaches the compartment where it is proposed to act, which is unresolved
- 02
Whether raising NAD+ building blocks in the bloodstream changes NAD+ concentration in the tissues that matter, as opposed to in the blood
- 03
Whether the enzyme mechanisms characterised in rodent obesity models operate the same way in human physiology at all
Constraints
Limitations worth holding onto
The evidence in this field is unusually uneven. NAD+ precursors carry a substantial number of randomised human trials; MOTS-c carries a handful; the NNMT inhibitor literature carries none. Reading them as one body of evidence would be a mistake — the per-compound trial counts are the honest view.
Mitochondrial measures are also hard to interpret. Many studies report a change in a marker of mitochondrial activity rather than a change in anything the organism actually does, and the distance between those two is where most overstatement in this field happens.
This field shares compounds with metabolic and longevity research rather than owning them. That overlap is real biology, not a taxonomy problem — but it does mean the same evidence appears under more than one heading, and it should not be counted twice.
Index
Compound classes in this area
NAD+ precursors
Trials and reviews describe nicotinamide mononucleotide and nicotinamide riboside as precursors that feed the NAD+ salvage pathway, with NAD+ then serving as a substrate the sirtuin and PARP enzymes consume.
Full reference page →
NNMT inhibitors (5-Amino-1MQ)
Published reviews describe inhibition of the enzyme nicotinamide N-methyltransferase (NNMT) and its role in cellular metabolism. Note that the indexed literature treats this as a small molecule, not a peptide.
Full reference page →
Sources
References for this field
Review articles covering the area as a whole, retrieved from PubMed. The explanatory sections above summarise what work of this kind reports.
This is a bibliographic and educational resource for research professionals. It is not medical, clinical, or legal advice, and nothing here is a recommendation to use any compound. Peptide research is an evolving field: what the literature contains changes as new work is published. Readers are responsible for evaluating the primary sources themselves and for consulting qualified professionals in their own jurisdiction.